GET DAILY SIGNALSWhy Is Exagen Inc. (XGN) Stock Down -16.32% Today?
Key Takeaways
- XGN shares fell roughly 16.32% in Thursday's session, dropping from a prior close of $7.60 to around $6.36.
- The primary catalyst was a sector-wide rout in diagnostics stocks, led by a sharp collapse in peer Veracyte after a disappointing volume outlook.
- A broader AI-led selloff pushed the Nasdaq toward correction territory, hitting high-beta, high-momentum small caps hardest.
- XGN, with a beta near 2.2, is especially vulnerable to risk-off rotation despite recent analyst price-target increases.
- Traders are now positioning ahead of Exagen's third-quarter earnings report, scheduled for Tuesday, November 10, 2026.
- For more detail on this stock, explore its Price Targets, Earnings, and Forecast pages.
- To see how AI-driven trading models are navigating this volatility, explore Trending AI Robots.
Opening Summary
Exagen Inc. (XGN), a commercial-stage diagnostics company that develops and markets autoimmune testing products under the AVISE brand, saw its stock tumble sharply in Thursday's session. Shares were trading near $6.36, down roughly $1.24, or about 16.32%, from the prior session's close of $7.60. The decline extended a multi-day pullback and came amid a broad, sentiment-driven selloff across the diagnostics and healthcare technology sectors, with no company-specific news from Exagen driving the move.
Sector-Wide Diagnostics Selloff
The most immediate pressure on XGN came from a sharp deterioration in sentiment across the diagnostics group. Peer VCYT (Veracyte) plunged by more than 50% after investors reacted negatively to a reduced outlook for its Decipher prostate test volume and to mid-single-digit revenue growth guidance for 2027, prompting a downgrade. That single-stock shock rippled through the broader precision-diagnostics complex, dragging down smaller, less liquid names such as XGN and other autoimmune and laboratory testing peers in sympathy.
Risk-Off Rotation in High-Beta Small Caps
Exagen's move also reflected a broader market dynamic rather than any fundamental change in its business. An AI-led pullback pushed the Nasdaq toward correction territory during the session, and high-momentum, high-beta equities bore the brunt of the selling. With a beta near 2.2, XGN tends to amplify broader index moves, leaving it especially exposed when investors rotate away from risk. The stock's elevated valuation relative to its still-negative earnings and its small float further magnified the intraday swings.
Pre-Earnings De-Risking
Compounding the selling is the timing of the company's next catalyst. Exagen is scheduled to report third-quarter financial results before the market opens on Tuesday, November 10, 2026. Ahead of that report, some investors appeared to be reducing positions, wary of holding a volatile small-cap name into a binary event. This de-risking dynamic, layered on top of the sector-wide rout, contributed to the outsized percentage decline.
Market Context and Trading Activity
The selloff in XGN diverged from a relatively contained move in the large-cap averages, underscoring how concentrated the pressure was in the diagnostics and high-momentum segments of the market. Trading volume was well above the stock's recent average, consistent with heavy rotation out of the name rather than a low-volume drift. The shares broke decisively below the $8 level that had acted as a technical floor in recent weeks, leaving the stock near the lower end of its recent trading range and below its 50-day moving average.
What Comes Next for XGN
Looking ahead, investors are focused on Exagen's November 10 earnings release. The company enters the report having posted record quarterly revenue and test volume in its second quarter, raised its full-year 2026 revenue guidance to $72–$75 million, and received a series of price-target increases from analysts. Still, the company remains unprofitable on a GAAP basis, and its trajectory depends on continued expansion in average selling price, test volume, and its emerging pharma services business. Key risks include reimbursement and coverage decisions, revenue-cycle timing variability, and the broader market's appetite for small-cap diagnostics names. Until sentiment in the sector stabilizes, near-term volatility is likely to persist.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of automated trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Because only the top performers are featured in this section, investors can use the page to monitor which algorithmic strategies are adapting most effectively to today's fast-moving market. Explore the Trending AI Robots to see how automated models are navigating the current volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for XGN turns positive, indicating new upward trend
XGN saw its Momentum Indicator move above the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 82 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XGN just turned positive on October 29, 2026. Looking at past instances where XGN's MACD turned positive, the stock continued to rise in 31 of 36 cases over the following month. The odds of a continued upward trend are 86%.
The 10-day moving average for XGN crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +11.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 157 of 185 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 45 cases where XGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
XGN moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. XGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.071) is normal, around the industry mean (66.084). P/E Ratio (-9.268) is within average values for comparable stocks, (2.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases
Industry MedicalSpecialties
Advertisement